Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company focused on gene therapies for serious ocular diseases. It develops engineered adeno-associated viral (AAV) vectors intended for intravitreal administration to enable sustained intraocular expression of therapeutic proteins, reducing reliance on frequent injections and other chronic treatments.
Its lead candidate, ixoberogene soroparvovec (Ixo-vec; formerly ADVM-022), is designed to deliver aflibercept for neovascular (wet) age-related macular degeneration, with clinical evaluation also in diabetic macular edema. Adverum’s work spans vector capsid design, expression cassette optimization, and analytical/process development for AAV-based products, alongside clinical strategies to manage inflammation associated with ocular gene therapy. The company traces its origins to Avalanche Biotechnologies and is headquartered in Redwood City, California.
Lilly's tender offer for Adverum shares expired, with 64% tendered. Acquisition completion expected Dec. 9, 2025. Legal and financial advisors involved.
